The First Hepatitis B Cure in Decades Just Got FDA Approval — and Most Patients Still Can't Stop Their Pills

For roughly 250 million people worldwide living with chronic hepatitis B, the goal has always been the same: get the virus low enough, for long enough, that the liver can finally rest. On October 20, 2026, the FDA approved Hibsago (bepirovirsen), the first antisense drug for chronic hepatitis B. It is the biggest shift in HBV care in a generation, but it is not a magic off-switch.

Key Takeaways

• On October 20, 2026, the FDA approved Hibsago (bepirovirsen) for certain adults with chronic hepatitis B without cirrhosis, under priority review, Fast Track, and Breakthrough Therapy designation (FDA, 2026).
• Patients take it alongside their existing HBV antiviral for at least 24 weeks after the last Hibsago injection before any medicine can be stopped (FDA, 2026).
• Only patients with suppressed HBV DNA and hepatitis B surface antigen (HBsAg) at or below 3,000 IU/mL qualify (FDA; Medscape, 2026).
• The most common side effects are injection-site reactions, fever, fatigue, and headache (FDA, 2026).

What Did the FDA Actually Approve?

Hibsago is an antisense oligonucleotide, a short synthetic strand of genetic material that silences the virus's own RNA. It is the first drug in this class ever cleared for chronic hepatitis B (FDA, 2026; Nature Reviews Drug Discovery, 2026). It is approved for adults without cirrhosis who have taken antiviral therapy for at least six months, have suppressed HBV DNA, and have HBsAg at or below 3,000 IU/mL (FDA, 2026).

Citation capsule: Hibsago (bepirovirsen) became the first FDA-approved antisense oligonucleotide for chronic hepatitis B on October 20, 2026, for non-cirrhotic adults already on antiviral therapy with suppressed virus and low surface antigen (FDA, 2026).

Why Can't Most Patients Stop Their Pills Right Away?

The virus hides inside liver cells as a closed circular DNA template called cccDNA, and no current drug fully clears it. Hibsago lowers surface antigen and viral RNA, but the liver still needs time to recover. Patients must continue their existing medicine for at least 24 weeks after the last injection, and only then, if lab tests show sustained suppression, may a clinician consider stopping (FDA, 2026).

Citation capsule: Even after Hibsago, patients continue their baseline antiviral for at least 24 weeks post-treatment before any stopping decision, because cccDNA persists in liver cells (FDA, 2026).

Who Qualifies — and Who Doesn't?

Qualification hinges on three numbers: six or more months on therapy, undetectable or suppressed HBV DNA, and HBsAg at or below 3,000 IU/mL (FDA; Medscape, 2026). People with cirrhosis are excluded. Patients with high surface antigen, recent therapy starts, or advanced fibrosis fall outside the label and should stay on standard treatment (FDA, 2026).

Citation capsule: Eligibility requires six-plus months of antiviral therapy, suppressed HBV DNA, and HBsAg at or below 3,000 IU/mL without cirrhosis; others remain on standard care (FDA; Medscape, 2026).

What Are the Side Effects?

The most common adverse events, excluding lab abnormalities, are injection-site reactions, fever, fatigue, and headache (FDA, 2026). Because Hibsago is injected, patients should plan for site care and monitoring. Clinicians also watch liver enzymes, since immune reactivation can flare during antigen decline (FDA, 2026).

Citation capsule: Hibsago's common side effects are injection-site reactions, fever, fatigue, and headache, with liver-enzyme monitoring during antigen decline (FDA, 2026).

What Does This Mean for the 250 Million People With HBV?

Hibsago does not cure everyone, and it does not remove cccDNA. But it is the first tool that reliably drives surface antigen down far enough that some patients may eventually stop daily pills. For a disease where most people stay on therapy for life, that is a real inflection point (FDA; Nature, 2026).

Citation capsule: Hibsago is the first therapy to consistently lower HBsAg enough that some patients may eventually stop lifelong antiviral pills, though cccDNA remains (FDA; Nature, 2026).

Frequently Asked Questions

Is Hibsago a cure for hepatitis B?

No. It lowers surface antigen and may allow some patients to stop medication later, but cccDNA persists in liver cells (FDA, 2026).

Can I stop my current HBV medicine now?

No. Patients must continue their existing antiviral for at least 24 weeks after the last Hibsago injection (FDA, 2026).

Who qualifies for Hibsago?

Non-cirrhotic adults on antiviral therapy for six-plus months with suppressed HBV DNA and HBsAg at or below 3,000 IU/mL (FDA; Medscape, 2026).

What are the side effects?

Injection-site reactions, fever, fatigue, and headache are most common (FDA, 2026).

Conclusion

Hibsago turns a lifelong suppression strategy into a possible path to stopping pills for a subset of patients. The label is narrow, the wait is long, and the virus's hidden template survives. But for the first time in decades, hepatitis B care has a new lever.

Sources

• U.S. FDA. FDA approves first-of-its-kind chronic hepatitis B treatment (Hibsago). October 20, 2026. Retrieved 2026-10-26. https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-chronic-hepatitis-b-treatment
• Medscape. FDA Approves Hibsago to Treat Patients With Certain Chronic HBV. October 22, 2026. Retrieved 2026-10-26. https://www.medscape.com/viewarticle/fda-approves-hibsago-treat-patients-certain-chronic-hbv-2026a10013qm
• Nature Reviews Drug Discovery. FDA approves hepatitis B antisense drug. October 21, 2026. Retrieved 2026-10-26. https://www.nature.com/articles/d41573-026-00166-7